TRACON Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 7 million compared to USD 7.71 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.4 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 USD | +5.46% | +3.76% | -44.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.89% | 4.39M | |
-2.35% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- TCON Stock
- News TRACON Pharmaceuticals, Inc.
- TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022